Back to Journals » Vascular Health and Risk Management » Volume 12

Targeting heart failure with preserved ejection fraction: current status and future prospects

Authors Kanwar M, Walter C, Clarke M, Aponte M

Received 8 December 2015

Accepted for publication 17 February 2016

Published 15 April 2016 Volume 2016:12 Pages 129—141

DOI https://doi.org/10.2147/VHRM.S83662

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Kaushik Shah

Peer reviewer comments 3

Editor who approved publication: Dr Daniel Duprez


Manreet Kanwar, Claire Walter, Megan Clarke, Maria Patarroyo-Aponte

Department of Cardiology, Allegheny General Hospital, Pittsburgh, PA, USA

Abstract: Heart failure with preserved ejection fraction (HFpEF) portrays a significant burden in terms of prevalence, morbidity, mortality, and health care costs. There is a lack of consensus on the basic pathophysiology, definition, and therapeutic targets for therapy for this syndrome. To date, there are no approved therapies available for reducing mortality or hospitalization for these patients. Several clinical trials have recently started to try and bridge this major gap. There is an urgent need to focus on drug and device development for HFpEF as well as to understand HFpEF pathophysiology.

Keywords: HFpEF therapies, diastolic dysfunction

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]